Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 165,708

Document Document Title
WO/2018/071663A1
RNA is a prefered composition for delivering genes to target cells for inducing genome editing. While RNA-guided DNA nucleases and their guide-RNA molecules can be easily delivered to a cell as RNA, a donor template is normally delivered...  
WO/2018/070521A1
In one embodiment, the present invention addresses the problem of: providing an agent for inhibiting a lectin pathway and an alternative pathway; and others. In one embodiment, the present invention relates to: a fusion polypeptide conta...  
WO/2018/068120A1
The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: a compound; the use of said compound; a synthetic intermediate in the preparation of comp...  
WO/2018/070069A1
The present invention provides a medicine comprising: a Toll-like receptor agonist; and LAG-3 protein, a variant thereof, or a derivative thereof.  
WO/2018/070390A1
The purpose of the present invention is to provide a pharmaceutical composition and the like used for treating or preventing angiogenic diseases. This pharmaceutical composition is a combination of a monoclonal antibody or antigen-bindin...  
WO/2018/070524A1
Provided are: a screening method suited for screening for a blood IgA production inhibitor, a blood IgA production accelerating agent, or a prophylactic or therapeutic agent against diseases caused by excessive IgA in the blood; a blood ...  
WO/2018/069907A1
Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-...  
WO/2018/066707A1
Provided are: a novel aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor; food and beverage products, pharmaceutical products, and cosmetic products which include said inhibitors; and a method for...  
WO/2018/067840A1
The present invention relates to a method of identifying targets for epigenetic reprogramming comprising detecting large organized heterochromatin lysine (K)-9 modified domains (LOCKs) and large DNA hypomethylated blocks in a sample cont...  
WO/2018/066427A1
The present invention addresses the problem of providing a composition for preventing and/or treating neurodegenerative diseases and cerebral infarction and a composition for improving learning disorders. Provided is a composition that c...  
WO/2018/066646A1
The present invention addresses the problem of finding a novel medicine which has an excellent tryptophanase inhibitory effect, suppresses indoxyl sulfate production in blood to thereby prevent deterioration of renal function, and thus c...  
WO/2018/060213A1
The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin r...  
WO/2018/059213A1
Provided are compounds interfering with SAICAR synthesis, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain co...  
WO/2018/062354A1
[Problem] To provide an intestinal microbiota improving agent which includes a powder or fine powder that contains eggshell membrane. Also to provide a composition for improving intestinal microbiota and for promoting type III collagen g...  
WO/2018/059211A1
Provided are applications of spermine and derivatives thereof. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds capab...  
WO/2018/059395A1
Provided are compounds weakening SAICAR synthase activity, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain c...  
WO/2018/060212A1
The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt%. The invention further relates...  
WO/2018/060311A1
The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preve...  
WO/2018/059739A1
The present invention describes a new method and new combination products for the therapy of neurological and other conditions which respond to dopaminergic therapies and especially to L-DOPA (L-Dihydroxy-Phenylalanine) based on the use ...  
WO/2018/056361A1
The purpose of the present invention is to provide a novel alkylating agent that binds specifically to immune checkpoint genes, that induces cell death, and that has a tumor-specific aggregating property. Provided are: a complex which sp...  
WO/2018/056269A1
These eye drops contain (3S, 4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine-8-yl) -N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxylic acid amide or a salt thereof, and have a pH of 4.0 to 9.0.  
WO/2018/055627A1
The present invention provides specific small molecule compounds that modulate degradation and stability of Wiskott-Aldrich Syndrome protein (WASp), methods and uses thereof in innate and acquired immune-related disorders or conditions, ...  
WO/2018/056412A1
The purpose of the present invention is to provide a Schwann cell differentiation promoter, a peripheral nerve regeneration promoter, or the like that contains an extract from inflamed tissue inoculated with vaccinia virus. The present i...  
WO/2018/055080A1
The present invention relates to methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof. The inventors demonstrated that DDA induces differentiation of tumor cells and stimulates the secr...  
WO/2018/057576A1
Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula I, which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-s...  
WO/2018/054354A1
Provided is an application of an SRC homology region 2-containing protein tyrosine phosphatase-1 agonist as represented by formula (I) in preparation of drugs for treating and reducing fibrosis. Preferably, the agonist is SC-43; the fibr...  
WO/2018/056301A1
Provided is a cancer stem cell inhibitor containing, as an active ingredient, an inhibitor of the forkhead box O3 (FOXO3)/liver kinase B1 (LKB1)/PPARγ coactivator 1β (PGC-1β)/pyruvate dehydrogenase α1 (PDHA1)/membrane associated ring...  
WO/2018/052065A1
Provided is a heterocyclic compound that can have a PRS inhibitory effect and is expected to be of use as a prophylaxis or a therapeutic agent for PRS-related diseases, including cancer. A compound or a salt thereof, said compound being ...  
WO/2018/052114A1
The present invention pertains to a pharmaceutical composition which contains a morphinan derivative exhibiting the action of an opioid δ receptor agonist. By administering the pharmaceutical composition provided by the present inventio...  
WO/2018/052058A1
The present invention provides: a heterocyclic compound which has an IRAK-4-inhibiting activity and is expected to be useful for the prevention/treatment of inflammatory diseases, autoimmune diseases, osteoarticular degenerative diseases...  
WO/2018/053397A1
The invention relates to methods of treating or preventing organophosphate poisoning in a subject in need thereof, comprising administering to the subject isoflurane, enflurane, halothane, sevoflurane, desflurane, xenon or argon in a the...  
WO/2018/052082A1
This Lin28a activator includes, as an active ingredient, a polysaccharide which contains at least one substance selected from the group consisting of ribose, xylose, and derivatives of each. A monocyte dedifferentiation inducer includes,...  
WO/2018/052066A1
Provided is a heterocyclic compound that can have a PRS inhibitory effect and is expected to be of use as a prophylaxis or a therapeutic agent for PRS-related diseases, including cancer. A compound or a salt thereof, said compound being ...  
WO/2018/053040A1
Methods of treatment of multiple sclerosis (MS) in humans, and in women in particular, comprising administering CHS-131 of the following formula: (I) or a pharmaceutically acceptable salt, prodrug or isomer of CHS-131.  
WO/2018/052002A1
Provided is a compound which can promote angiogenesis by inhibiting the function of TSP1, and is useful in the treatment or prevention of diseases such as critical limb ischemia. Specifically provided is a macrocyclic polypeptide represe...  
WO/2018/052142A1
The purpose of the present invention is to produce chimeric antigen receptor (CAR)-expressing cells having superior target cell cytotoxicity. Provided are genetically-modified cells obtained by introducing polynucleotides that encode c...  
WO/2018/047884A1
The present invention addresses the problem of removing platelets from apheresis blood. Mononuclear cells are prepared while avoiding contamination with platelets. The present invention provides a method for preparing mononuclear cells, ...  
WO/2018/047715A1
The purpose of the present invention is to provide: crystals of β-nicotinamide mononucleotide (NMN) which have excellent storage stability; and a production process therefor. According to the present invention, crystals of NMN can be pr...  
WO/2018/047888A1
The present invention provides a compound that has an exceptional TLR4 signal-inhibiting action and can be useful as a drug for the prevention or treatment of autoimmune diseases and/or inflammatory diseases or diseases such as chemother...  
WO/2018/049003A1
The present disclosure relates to anti-fibrotic sialidase-inhibitor compounds and methods of preventing or inhibiting fibrosis using such compounds. The present disclosure also relates to methods of controlling the formation of fibrocyte...  
WO/2018/047894A1
Provided is a novel antibody. According to the present invention, a monoclonal antibody or a binding fragment thereof binds to domain 3 of a human LAG-3, and has the properties described in (i) and (vi) and one or more of the properties ...  
WO/2018/047848A1
To provide a nerve regeneration-inducing tube having improved properties and a material thereof. A compound having a structure in which (A) to (C) are bonded together and (B) and (C) are adjacent to each other: (A) an oligomer comprising...  
WO/2018/043463A1
Provided is a drug for removing aged cells or a medicinal composition therefor, said drug or composition comprising an SGLT2 inhibitor.  
WO/2018/043530A1
The present invention addresses the problem of providing: an anti-tumor agent having a superior anti-tumor effect compared with a therapy with gemcitabine, paclitaxel or a combination thereof; an anti-tumor kit; and an anti-tumor effect ...  
WO/2018/043747A1
Provided is an anti-hepatitis B virus drug which comprises a compound having a specific structure or a salt thereof and can exhibit an interferon-like activity.  
WO/2018/043596A1
The present invention provides: a method for producing a cell culture for the promotion of angiogenesis or the promotion of axonal outgrowth, particularly the treatment of a cerebrovascular disorder, an ischemic heart disease or a trauma...  
WO/2018/043674A1
Provided are: a composition for activating neurogenesis; use of the same; and a method for preventing, improving, inhibiting the progress and/or treating disorders and the like of the central and/or peripheral nervous systems. The presen...  
WO/2018/039748A1
Peptides derived from the N-terminal region of granulin have activity in promoting cell proliferation, migration and/or wound healing. Furthermore, an additional disulphide bond may be engineered into such peptides to improve or otherwis...  
WO/2018/043734A1
The present inventors have conducted diligent studies and consequently created anti-TGF-beta 1 antibodies which inhibit a protease mediated activation of TGF-beta 1. It has been reported that latent TGF-beta is cleaved to release active ...  
WO/2018/039581A1
The present disclosure is directed to the use of HDAC6 inhibitors for the treatment of renal diseases and disorders, including ciliopathy, Von Hippel-Lindau (VHL) disease, renal cystogenesis, renal cell carcinoma, and Tuberous Sclerosis ...  

Matches 1 - 50 out of 165,708